Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

The present disclosure provides a method for determining the amount of albumin in a sample. In one embodiment, the method involves treating the sample with an esterase inhibitor that selectively inhibits non-albumin esterase activity; combining the sample with a selective substrate of albumin, which has a carboxylic ester bond, so that the carboxylic ester bond is cleaved to generate a hydrolysate; detecting the amount of the hydrolysate generated in a period of time; and determining the amount of the albumin in the sample based on the amount of the hydrolysate in the period of time.

Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.

The present invention relates to a sentinel lymph node marker comprising an albumin; a radioactive isotope and/or near infrared dye which is bound to the albumin; and a visible dye which is bound to the albumin, a preparation method thereof, and a kit for multimode imaging of a sentinel lymph node to prepare the sentinel lymph node marker. The sentinel lymph node marker of the invention remains in the sentinel lymph node for a long period of time and allows for multimode imaging of the sentinel lymph node. Thus, using this marker the sentinel lymph node can be accurately identified in vivo by near infrared imaging and/or gamma imaging without incision of skin, and the location of the identified sentinel lymph node can be precisely identified with the naked eye during a surgical operation of removing the identified sentinel lymph node.

Silica nanoparticles for biomarker diagnosis and a method of manufacturing the same, and more particularly silica nanoparticles for biomarker diagnosis capable of measuring glycated proteins such as glycated hemoglobin, glycated albumin, etc. used as diabetes diagnosis markers, and a method of manufacturing the same are proposed. The silica nanoparticles for biomarker diagnosis, containing a reactive polymer and a nonreactive polymer immobilized on the surface and a dye immobilized inside, immobilize the dye therein through covalent bonding, whereby the dye is not affected by external environmental factors such as heat, pH, etc., and stability is enhanced even upon long-term storage.

A blocking reagent for immunohistochemical staining containing succinylated BSA as an active ingredient.

An electrochemically active, creatinine-binding device is provided to detect and measure quantitatively, creatinine in biological samples. The device of the present invention is also provided with a device to detect and measure quantitatively creatinine and albumin bioanalytes, simultaneously and to determine albumin to creatinine ratio (ACR). The present invention also provides an electrochemically active, creatinine-binding and albumin-binding device, for collection and retention of biological samples, having creatinine and albumin bioanalytes. In the present invention, a device holder is provided to receive the electrochemically active, creatinine-binding and albumin-binding device. The device, point-of-care biosensor and the method of the present invention, facilitate quantitative measurement of creatinine and albumin bioanalytes in urine and blood samples, and albumin to creatinine ratio (ACR), in urine samples, electrochemically, by determining redox current values.

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.

Disclosed are methods of detecting biomarkers in complex biological matrices. The method comprises providing a sample well coated with antibodies specific to target protein biomarker(s), contacting the sample well with a biological sample to capture target biomarkers, digesting target biomarkers, and analyzing the signature peptides resulting from digestion of target biomarkers to determine the amount of one or more protein biomarkers by a mass spectrometry method.

The disclosure discloses a method for detecting a human soluble asialoglycoprotein receptor, and belongs to the field of immunological detection. The disclosure provides an economical, rapid, accurate and highly practical ELISA method for detecting a human sASGPR. Based on the specific recognition between a specific ligand of ASGPR and ASGPR, the method selects galactosylated human serum albumin (GSA) as the specific ligand of ASGPR. GSA is prepared from human serum albumin, and has the advantages of cheap price, easy operation, easy storage and the like, and the limit of detection of the method is suitable for the detection of sASGPR in human serum samples. The method can be carried out in ordinary laboratories without using special, large-scale instruments and equipment. The method has the advantages of high specificity, good stability, simple and convenient operation, low cost and the like, and provides a certain reference value for clinical liver function evaluation.